Are you Dr. Peacock?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 68 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2004 Hayes St
Ste 350
Nashville, TN 37203Phone+1 615-312-3333Fax+1 615-320-7091
Summary
- Dr. Nancy Peacock, MD is an oncologist in Nashville, Tennessee. She is currently licensed to practice medicine in Tennessee and Texas. She is affiliated with Ascension Saint Thomas, TriStar Centennial Medical Center, and TriStar NorthCrest Medical Center.
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1991 - 1993- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 1988 - 1991
University of Missouri-Columbia School of MedicineClass of 1988
Certifications & Licensure
TN State Medical License 1995 - 2026
TX State Medical License 1989 - 1996- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Retrospective Cohort Study of Infusion Reactions Due to Vectibix Start of enrollment: 2010 Jun 01
Publications & Presentations
PubMed
- 90 citationsPhase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast CancerAnna Maria Storniolo, Mark D. Pegram, Beth Overmoyer, Paula Silverman, N. W. Peacock
Journal of Clinical Oncology. 2008-07-10 - 43 citationsA phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response ...Denise A. Yardley, N. W. Peacock, Mythili Shastry, Howard A. Burris, Rebecca Bechhold
Breast Cancer Research and Treatment. 2015-10-27 - 6 citationsA Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera
Clinical Breast Cancer. 2021-10-28
Professional Memberships
- Member
